Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Concomitant Omicron COVID-19 and Influenza Vaccines
NCT06091410Phase 4Active, not recruiting
- Sponsor
- Catholic Kwandong University
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Catholic Kwandong University. Primary endpoint: Geometric Mean Titer against SARS-CoV-2. Started Sep 2023; status: active, not recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06091410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091410.